LB Pharmaceuticals
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Penn Plz Ste 1025, New York, New York,...Phone Number
(212) 605-0300Website
www.lbpharma.usRevenue
-Stock Symbol
LBRXIndustry
About LB Pharmaceuticals
LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in New York, New York, developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product candidate, LB-102, is an oral small molecule benzamide antipsychotic derived from amisulpride currently advancing through Phase 3 clinical trials for acute schizophrenia, with additional development underway for bipolar I depression and adjunctive treatment of major depressive disorder. Founded in 2015, LB Pharmaceuticals trades publicly on the NASDAQ under the ticker LBRX.Explore more
LB Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to LB Pharmaceuticals
Compare insights from companies similar to LB Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
LB Pharmaceuticals Tech Stack
A closer look at the technologies used by LB Pharmaceuticals
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LB Pharmaceuticals
Sign Up For FreeTo access detailed company insights
LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in New York, New York, developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product candidate, LB-102, is an oral small molecule benzamide antipsychotic derived from amisulpride currently advancing through P... Read More
